Pharmacokinetic model describing the disposition of butadiene and styrene in mice

Toxicology

Volumn 113, Issue 1-3, 1996, Pages 310-313

  Leavens, Teresa L ^a,b,c   Bond, James A ^b  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b CIIT CENTERS FOR HEALTH RESEARCH   (United States)

^c U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

Author keywords

butadiene; interactions; mixture; physiologically based pharmacokinetic model; styrene

Indexed keywords

1,3 BUTADIENE; STYRENE;

ANIMAL EXPERIMENT; CHEMICAL INTERACTION; CONFERENCE PAPER; CONTROLLED STUDY; INHALATION; MALE; MODEL; MOUSE; NONHUMAN; OXIDATION; PHARMACOKINETICS; PRIORITY JOURNAL; TOXICOKINETICS; XENOBIOTIC METABOLISM;

ANIMALIA;

EID: 0030605090     PISSN: 0300483X     EISSN: None     Source Type: Journal    
DOI: 10.1016/0300-483X(96)03463-4     Document Type: Conference Paper

References (13)

1. Boogard, P., Sumner, S.C.J. and Bond, J.A. (1995) Glutathione conjugation of 1,2:3,4-diepoxybutane in human liver and rat and mouse liver and lung in vitro. Toxicol. Appl. Pharmacol. (in press).
2. Csanády, G.A., Guengerich, F.P. and Bond, J.A. (1992) Comparison of the biotransformation of 1,3-butadiene and its metabolite, butadiene monoepoxide by hepatic and pulmonary tissues from humans, rats, and mice. Carcinogenesis 13, 1143-1153.
3. Csanády, G.A., Mendrala, A.L., Nolan, R.J. and Filser, J.G. (1994) A physiologic pharmacokinetic model for styrene and styrene-7,8-oxide in mouse, rat, and man. Arch. Toxicol. 68, 143-157.
4. Duescher, R.J. and Elfarra, A.A. (1994) Human liver microsomes are efficient catalysts of 1,3-butadiene oxidation: evidence for major roles by cytochrome P450 2A6 and 2E1. Arch. Biochem. Biophys. 311, 342-349.
5. Leavens, T.L., Moss, O.R. and Bond, J.A. (1996b) Dynamic inhalation system for individual whole body exposure of mice to volatile organic chemicals. Inhal. Toxicol., in press.
6. Leavens, T.L., Moss, O.R., Turner, M.J., Janszen, D.B. and Bond, J. A. (1996a) Metabolic interactions of 1,3-butadiene and styrene in male B6C3F1 mice. Toxicol. Appl. Pharmacol., in press.
7. Leibman, K. (1975) Metabolism and toxicity of styrene. Environ. Health Perspect. 11, 115-119.
8. Löf, A., Gullstrand, E. and Nordqvist, M.B. (1983) Tissue distribution of styrene, styrene glycol and more polar styrene metabolites in the mouse. Scand. J. Work Environ. Health 9, 419-430.
9. Malvoisin, E., Lhoest, G., Poncelet, F., Roberfroid, M. and Mercier, M. (1979) Identification and quantitation of 1,2-epoxybutene-3 as the primary metabolite of 1,3-butadiene. J. Chromatogr. 178, 419-425.
10. Medinsky, M.A., Leavens, T.L., Csandy, G.A., Gargas, M.L. and Bond, J.A. (1994) In vivo metabolism of butadiene by mice and rats: a comparison of physiological model predictions and experimental data. Carcinogenesis 15, 1329-1340.
11. Nakajima, T., Wang, R.-S., Elovaara, E., Gonzalez, F.J., Gelboin, H.V., Vainio, H. and Aoyama, T. (1994) Cyp2C11 and Cyp2B1 are major cytochrome P450 forms involved in styrene oxidation in liver and lung microsomes from untreated rats, respectively. Biochem. Pharmacol. 48, 637-642.
12. Ramsey, J.C. and Andersen, M.E. (1984) A physiologically based description of the inhalation pharmacokinetics of styrene in rats and humans. Toxicol. Appl. Pharmacol. 73, 159-175.
13. Sabourin, P.J., Burka, L.T., Bechtold, W.E., Dahl, A.R., Hoover, M.D., Chang, I.Y. and Henderson, R.F. (1992) Species differences in urinary butadiene metabolites; identification of 1,2-dihydroxy-4-(N-acetylcysteinyl)butane, a novel metabolite of butadiene. Carcinogenesis 13(9), 1633-1638.